<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627611</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1883 (REK)</org_study_id>
    <secondary_id>2017-003673-34</secondary_id>
    <nct_id>NCT03627611</nct_id>
  </id_info>
  <brief_title>Identification of Non-responders to Levothyroxine Therapy</brief_title>
  <official_title>A Randomized Crossover Study, Examining Differential Effects of Levothyroxine and Liothyronine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hormonlaboratoriet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spesialistsenteret Pilestredet Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess differential effects of T4 and T3 on cell and tissue
      level
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      15-20% of the patients with hypothyroidism remain symptomatic, despite adequate thyroxine
      substitution. Endocrinologists are split in their opinion on combination therapy with T4 and
      T3 on patients with poorly regulated hypothyroidism. There are no objective means, by which
      to identify individuals who would benefit from combination therapy. The purpose of this study
      is to assess differential effects of T4 and T3 on body temperature, metabolism, muscle
      strength and brain function. The main aim is to try to identify biomarkers reflecting
      different effects of T4 and T3 on cell and tissue level.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New biomarkers</measure>
    <time_frame>6 months</time_frame>
    <description>Bone marrow fat, serum and urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>6 months</time_frame>
    <description>Thermography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>6 months</time_frame>
    <description>Hand grip test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome measures</measure>
    <time_frame>6 months</time_frame>
    <description>ThyPro-39 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean levels of thyroid hormones</measure>
    <time_frame>6 months</time_frame>
    <description>TSH, free T4 and free T3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypothyroidism</condition>
  <condition>Biomarkers</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxin</intervention_name>
    <description>3 months</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>3 months</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poorly regulated hypothyroidism

          -  Female aged between 18 and 65 years

          -  Written informed consent obtained from the patient according to national regulations

        Exclusion Criteria:

          -  Cardiovascular disease

          -  Chronic liver disease

          -  Chronic kidney disease

          -  Any other endocrinological disease

          -  Use of beta blockers

          -  Pregnant or lactating females

          -  Hormonal substitution other than T3 and T4

          -  Known psychiatric disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Fink Eriksen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Morbid Obesity and Preventive Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Fink Eriksen, Professor</last_name>
    <phone>+47 92470122</phone>
    <email>erik.fink.eriksen@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betty Ann Bjerkreim, MD</last_name>
    <phone>+47 92269971</phone>
    <email>Betty.Ann.Bjerkreim@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Fink Eriksen, Professor</last_name>
      <email>e.f.eriksen@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Betty Ann Bjerkreim, MD</last_name>
      <email>bettyannbn@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Erik Fink Eriksen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Thyroxine</keyword>
  <keyword>Triiodothyronine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

